J&J Inks Potential $500M Deal With Astex
This article was originally published in The Pink Sheet Daily
U.K. firm’s FGFR cancer program brings “significant financials,” CEO tells “The Pink Sheet” DAILY.
You may also be interested in...
The deal brings private Astex a long-sought NASDAQ listing and beefs up cash-rich SuperGen's lackluster pipeline.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.